Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

vaxcyte - PCVX

PCVX

Close Chg Chg %
69.85 3.39 4.85%

Pre-Market

73.24

+3.39 (4.85%)

Volume: 1.35M

Last Updated:

Mar 12, 2025, 4:00 PM EDT

Trade Now

Company Overview: vaxcyte - PCVX

PCVX Key Data

Open

$70.00

 Day Range

70.00 - 75.00

52 Week Range

58.10 - 121.06

 Market Cap

$9.43B

Shares Outstanding

128.76M

 Public Float

125.00M

Beta

1.02

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$3.88

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.28M

  

PCVX Performance

1 Week
 
 -1.87%
 
1 Month
 
 -16.85%
 
3 Months
 
 -20.37%
 
1 Year
 
 0.22%
 
5 Years
 
 N/A
 

PCVX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 9
Full Ratings ➔

About vaxcyte - PCVX

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

PCVX At a Glance

Vaxcyte, Inc.
825 Industrial Road
San Carlos, California 94070
Phone 1-650-837-0111 Revenue 0.00
Industry Biotechnology Net Income -463,927,000.00
Sector Health Technology Employees 414
Fiscal Year-end 12 / 2025
View SEC Filings

PCVX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 3.093
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -15.009
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.009

PCVX Efficiency

Revenue/Employee N/A
Income Per Employee -1,120,596.618
Receivables Turnover N/A
Total Asset Turnover N/A

PCVX Liquidity

Current Ratio 12.755
Quick Ratio 12.755
Cash Ratio 12.464

PCVX Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -18.778
Return on Equity -20.409
Return on Total Capital -13.738
Return on Invested Capital -20.024

PCVX Capital Structure

Total Debt to Total Equity 2.151
Total Debt to Total Capital 2.106
Total Debt to Total Assets 2.013
Long-Term Debt to Equity 1.973
Long-Term Debt to Total Capital 1.931
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Vaxcyte - PCVX

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
1.80M 9.20M 10.17M 15.85M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.80M 9.20M 10.17M 15.85M
Depreciation
1.80M 9.20M 10.17M 15.85M
Amortization of Intangibles
- - - -
-
COGS Growth
+28.11% +410.89% +10.60% +55.79%
Gross Income
(1.80M) (9.20M) (10.17M) (15.85M)
Gross Income Growth
-28.11% -410.89% -10.60% -55.79%
Gross Profit Margin
- - - -
-
2021 2022 2023 2024 5-year trend
SG&A Expense
101.87M 200.06M 382.87M 553.70M
Research & Development
78.41M 169.45M 332.34M 476.64M
Other SG&A
23.46M 30.61M 50.53M 77.06M
SGA Growth
+15.53% +96.39% +91.37% +44.62%
Other Operating Expense
- - - -
-
Unusual Expense
- - 23.00M 75.00M
-
EBIT after Unusual Expense
(103.67M) (232.26M) (468.04M) (569.55M)
Non Operating Income/Expense
3.59M 8.77M 65.78M 105.62M
Non-Operating Interest Income
344.00K 8.36M 62.91M 109.99M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -100.00%
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(100.08M) (223.49M) (402.27M) (463.93M)
Pretax Income Growth
-12.17% -123.31% -80.00% -15.33%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(100.08M) (223.49M) (402.27M) (463.93M)
Minority Interest Expense
- - - -
-
Net Income
(100.08M) (223.49M) (402.27M) (463.93M)
Net Income Growth
-12.17% -123.31% -80.00% -15.33%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(100.08M) (223.49M) (402.27M) (463.93M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(100.08M) (223.49M) (402.27M) (463.93M)
EPS (Basic)
-1.9274 -3.4447 -4.1403 -3.8028
EPS (Basic) Growth
-10.33% -78.72% -20.19% +8.15%
Basic Shares Outstanding
51.92M 64.88M 97.16M 122.00M
EPS (Diluted)
-1.9274 -3.4447 -4.1403 -3.8028
EPS (Diluted) Growth
-10.33% -78.72% -20.19% +8.15%
Diluted Shares Outstanding
51.92M 64.88M 97.16M 122.00M
EBITDA
(101.87M) (200.06M) (382.87M) (553.70M)
EBITDA Growth
-15.53% -96.39% -91.37% -44.62%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 149.889
Number of Ratings 9 Current Quarters Estimate -1.037
FY Report Date 03 / 2025 Current Year's Estimate -4.521
Last Quarter’s Earnings -1.02 Median PE on CY Estimate N/A
Year Ago Earnings -3.80 Next Fiscal Year Estimate -4.645
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 7 7 9 8
Mean Estimate -1.04 -1.08 -4.52 -4.65
High Estimates -0.81 -0.86 -3.47 -2.39
Low Estimate -1.26 -1.29 -5.60 -5.46
Coefficient of Variance -15.87 -15.09 -14.88 -21.94

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 9 9 11
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Vaxcyte - PCVX

Date Name Shares Transaction Value
Feb 20, 2025 Andrew L. Guggenhime PRESIDENT AND CFO 246,827 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Andrew L. Guggenhime PRESIDENT AND CFO 109,491 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $84.58 per share 9,260,748.78
Feb 20, 2025 Andrew L. Guggenhime PRESIDENT AND CFO 111,309 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $83.64 per share 9,309,884.76
Feb 20, 2025 Andrew L. Guggenhime PRESIDENT AND CFO 117,491 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $5.35 per share 628,576.85
Jan 6, 2025 James Wassil CHIEF OPERATING OFFICER 206,856 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $83.69 per share 17,311,778.64
Jan 6, 2025 James Wassil CHIEF OPERATING OFFICER 205,695 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $84.43 per share 17,366,828.85
Jan 6, 2025 James Wassil CHIEF OPERATING OFFICER 10,638 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 6, 2025 James Wassil CHIEF OPERATING OFFICER 212,339 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $82.88 per share 17,598,656.32
Jan 6, 2025 James Wassil CHIEF OPERATING OFFICER 213,695 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $2.42 per share 517,141.90
Oct 4, 2024 Grant E. Pickering CHIEF EXECUTIVE OFFICER; Director 450,219 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $114.98 per share 51,766,180.62
Oct 4, 2024 Grant E. Pickering CHIEF EXECUTIVE OFFICER; Director 218,717 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 4, 2024 Grant E. Pickering CHIEF EXECUTIVE OFFICER; Director 238,717 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 4, 2024 Grant E. Pickering CHIEF EXECUTIVE OFFICER; Director 455,693 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $114.28 per share 52,076,596.04
Oct 4, 2024 Grant E. Pickering CHIEF EXECUTIVE OFFICER; Director 465,320 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $113.37 per share 52,753,328.40
Oct 4, 2024 Grant E. Pickering CHIEF EXECUTIVE OFFICER; Director 470,219 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $5.35 per share 2,515,671.65
Oct 4, 2024 Grant E. Pickering CHIEF EXECUTIVE OFFICER; Director 456,485 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $114.2 per share 52,130,587.00
Oct 4, 2024 Grant E. Pickering CHIEF EXECUTIVE OFFICER; Director 465,914 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $113.35 per share 52,811,351.90
Oct 4, 2024 Grant E. Pickering CHIEF EXECUTIVE OFFICER; Director 470,219 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $5.35 per share 2,515,671.65
Oct 4, 2024 Grant E. Pickering CHIEF EXECUTIVE OFFICER; Director 450,219 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $114.98 per share 51,766,180.62
Oct 4, 2024 Grant E. Pickering CHIEF EXECUTIVE OFFICER; Director 454,507 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $114.27 per share 51,936,514.89

Vaxcyte in the News